Khiron Life Sciences Corp. (KHRNF)
| Market Cap | 232.00 |
| Revenue (ttm) | 11.75M +38.2% |
| Net Income | -22.33M |
| EPS | -0.12 |
| Shares Out | 232.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27,000 |
| Open | 0.000001 |
| Previous Close | 0.000001 |
| Day's Range | 0.000001 - 0.0001 |
| 52-Week Range | n/a |
| Beta | 21.05 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Khiron Life Sciences
Khiron Life Sciences Corp. operates as a medical cannabis company in Latin America and Europe. It engages in the cultivation, production, distribution, and export of tetrahydrocannabinol medical cannabis products. The company is also involved in the operation of health centers under the Zerenia and Dr. Zerenia brand names; and provision of medical education and training programs for health professionals. It sells its products in Colombia, Peru, Germany, the United Kingdom, Brazil, Uruguay, and Mexico. The company is headquartered in Bogota, Col... [Read more]
Full Company ProfileNews
Khiron Life Sciences Announces Closing of the Sale of Its European Business
Toronto, Ontario--(Newsfile Corp. - November 17, 2023) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) ("Khiron" or the "Company") is pleased to announce that the Company has completed the sa...
Khiron Life Sciences Announces Update to the Proposed Sale of Its European Business
Toronto, Ontario--(Newsfile Corp. - November 16, 2023) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTC Pink: KHRNF) ("Khiron" or the "Company") today announced that the Company and 2518542 Alberta Ltd....
Khiron Life Sciences Agrees to $500,000 Secured Deposit
Toronto, Ontario--(Newsfile Corp. - June 5, 2023) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) ("Khiron" or the "Company") announced today that the Company has agreed to a $500,000 non-in...
Medical First: Germany Strengthens Reimbursement of Medical Cannabis
On 16 March 2023, after five years of observational data collection the German Federal Joint Committee (G-BA) decided on the future regulations that will govern the prescription of medical cannabis as...
Khiron Completes First Phase of Business Optimization
First phase of optimization was focused on streamlining Colombian operations, resulting in a moving forward annualized cost reduction of CAD 5.0 million, representing overall cost savings of more than...
Khiron Life Sciences Announces Closing of Marketed Offering Including Full Exercise of Over-Allotment Option
Toronto, Ontario--(Newsfile Corp. - April 4, 2023) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) ("Khiron" or the "Company") is pleased to announce that it has closed today its previously a...
Khiron Closes Additional Loan with Investment-Grade Bank
The term loan, provided by one of Colombia's largest and traditional private banks, provides immediate access to liquidity, and further strengthens Khiron's credibility with long-established banking i...
Khiron Closes Revolving Credit Facility with Financing Company in Colombia
Toronto, Ontario--(Newsfile Corp. - February 14, 2023) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) (FSE: A2JMZC) ("Khiron" or the "Company"), announces that its wholly owned subsidiary Ze...
Khiron begins dispensation of insurance-covered prescriptions in Colombia
Following the Government of Colombia's decision on insurance coverage for medical cannabis, Khiron has begun dispensing medical cannabis to its patient base under the new mandate. TORONTO , Jan. 19, 2...
NHS reimburses the cost of cannabis treatment to the first Zerenia™ Clinics UK patient
Zerenia™ Clinics UK, wholly owned by Khiron, succeeds at having the NHS reimbursing both the cost of cannabis-based treatment and clinic fees to its first patient Khiron trains doctors and nurses at a...
Khiron wins first medical cannabis contract with Colombia's largest public insurance company
On December 27, 2022, Zerenia (Khiron´s wholly owned medical cannabis clinic network) signed a contract with CAPITAL SALUD EPS, Colombia´s largest public insurance company, under which Zerenia will pr...
Government of Colombia Declares Mandatory Insurance Coverage for Medical Cannabis Products
On December 30, 2022, the Ministry of Health of Colombia reaffirmed the inclusion of plant-based medical cannabis products, i.e., Khiron products, in the mandatory insurance coverage system Starting J...
Khiron Life Sciences Earnings Call Transcript: Q3 2022
Khiron Life Sciences Earnings release: Q3 2022
Khiron Life Sciences released its Q3 2022 earnings on November 30, 2022, summarizing the period's financial results.
Khiron Life Sciences Reports Third Quarter 2022 Financial Results
In Europe, revenues increased by 141% year-over-year, driven by revenues in the United Kingdom, where the Corporation is now increasing its existing product portfolio, and the specialized cannabis cli...
Khiron to Host Third Quarter 2022 Conference Call on November 30, 2022
TORONTO , Nov. 18, 2022 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMXC), the global leader in medical cannabis throughout Latin Am...
Khiron begins sales in Switzerland and expands its medical cannabis portfolio in Germany and the United Kingdom
Through its newly acquired EU-GMP distribution hub in Germany, Khiron expands its product portfolio and geographic reach within Europe to Germany, UK, and Switzerland. Switzerland: Khiron enters the S...
Khiron, the Global Leader in Medical Cannabis Launches New Cannabis Products in Europe including Stellar Genetics from California
New products to be distributed through Khiron's new wholly-owned subsidiary Pharmadrug Production GmbH Khiron introduces new THC-dominant full-spectrum extract KHIRIOX 25/1, and non-irradiated flower ...
Khiron Life Sciences Reports Second Quarter 2022 Financial Results
Reports revenues of $9.1 million in the first half of 2022, up 62% year-over-year, reflecting continued medical cannabis momentum in target markets Recorded its lowest ever Adjusted EBITDA loss in Q2 ...
Khiron Life Sciences Earnings Call Transcript: Q2 2022
Khiron Life Sciences Earnings release: Q2 2022
Khiron Life Sciences released its Q2 2022 earnings on August 29, 2022, summarizing the period's financial results.
Khiron to Host Second Quarter 2022 Conference Call on August 29, 2022
TORONTO , Aug. 22, 2022 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN)(OTCQX: KHRNF)(Frankfurt: A2JMXC), the global leader in medical cannabis throughout Latin Amer...
Khiron Life Sciences Corp. to Present at Investor Summit Group's Q3 Virtual Conference
Toronto, Ontario--(Newsfile Corp. - August 10, 2022) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (FSE: A2JMZC) ("Khiron" or the "Company"), a global leader in medical cannabis throughout ...
Medical Cannabis Leader Khiron Opens Brazil's First Zerenia™ Clinic
Continued Global Growth of Khiron's Proven ZereniaTM Clinic ModelFocused on Patients, Physician Education and Innovation New clinic is in the district of Ipanema in Rio de Janeiro, a city with more th...
Khiron Completes Acquisition of Pharmadrug Production GmbH, Establishing German Pharmaceutical Distribution Capabilities
Acquisition provides Khiron with an EU-GMP European manufacturing and distribution hub for medical cannabis and other pharmaceutical products The acquisition of Pharmadrug Production GmbH provides Khi...